ClinicalTrials.gg
CompletedNCT01059539Updated Jun 13, 2019Results posted

Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder

A Phase 3 interventional study of Cariprazine in Bipolar I Disorder, sponsored by Forest Laboratories. Completed at 35 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-06-13.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
403
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies in Mania with a site in United States — 5 open to participants now, 5 under way, 4 of them phase 3. Mania · United States.

Enrollment
11th of 88
403 · median 83
Started
2010
with 8 others
Phase 3
32 of 94
4 open now
Registered
64th of 94
by date
Lead sponsor
5 of 94
Forest Laboratories

Among the 94 studies in Mania with a site in United States, this one is the 11th largest by enrollment of the 88 interventional ones that give a count, is one of 9 that started in 2010, is one of 32 in phase 3, and was the 64th registered.

Mania

167 studies on the registry are indexed under Mania; 14 are open to participants now.

Browse Mania studies →

Open to participants now

5 of the 94 studies in Mania with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Mania studies recruiting now, 5 (42%) set no upper age limit and 7 (58%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Mania with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with bipolar I disorder.

03

Conditions studied

  • Bipolar I Disorder

Browse trials for

Keywords

  • Mania
  • Acute mania
  • Bipolar I disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have provided prior to any study specific procedures.
  • Patients currently meeting the , Fourth Edition, Text Revision (DSM-IV-TR) criteria for bipolar I disorder as confirmed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (SCID).
  • Patients who experienced a manic or mixed episode that required treatment within the past 12 months.
  • Patients with normal physical examination, laboratory, vital signs, and (ECG).

Exclusion criteria

Exclusion Criteria:

  • Patients with a diagnosis of an axis I disorder other than bipolar I disorder.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
403 participants (actual)

Study arms

  • Experimental
    Cariprazine 3-12 mg/day for 16 weeks

    Participants received cariprazine 1.5 mg orally on Day 1 and cariprazine 3.0 mg orally on Days 2 and 3. Starting on Day 4, the dose could be increased in increments of 3 mg every 2 days up to a maximum dose of 12 mg, if the response was not adequate and there were no tolerability issues based on the judgment of the principal investigator.

    Drug: Cariprazine

Interventions

  • Cariprazine was supplied in capsules.

    Also known as: RGH-188

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the YMRS Total Score at Week 16

    The Young Mania Rating Scale (YMRS) is an 11-item scale that assesses manic symptoms based on the patient's perception of his or her condition over the previous 48 hours, as well as the physician's clinical observations during the interview. The 11 items are elevated mood, increased motor activity-energy, sexual interest, sleep, irritability, rate and amount of speech, language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight. The severity of each item is rated on a 5-point (0-4) or a 9-point (0-8) scale. The total score of all 11 items can range from 0 to 60. A higher score indicates worse manic symptoms. A negative change score indicates improvement.

    Time frame: Baseline to Week 16

Secondary outcomes

  1. Change From Baseline in the MADRS Total Score at Week 16

    The Montgomery-Asberg Depression Rating Scale (MADRS) is a clinician-rated scale that evaluates the patient's depressive symptomatology during the previous week. Patients are rated on 10 items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item is scored on a 7-point (0-6) scale. The total score can range from 0 to 42. A higher score indicates greater depressive symptomatology. A negative change score indicates improvement.

    Time frame: Baseline to Week 16

07

Results

Posted Jun 13, 2019

Participant flow

Participant flow — Overall Study
MilestoneCariprazine 3-12 mg/Day for 16 Weeks
Started403
Completed132
Not completed271
Withdrew: Adverse event66
Withdrew: Insufficient therapeutic response26
Withdrew: Protocol violation55
Withdrew: Withdrawal of consent80
Withdrew: Lost to follow-up42
Withdrew: Reason not specified2

Outcome measures

PrimaryChange From Baseline in the YMRS Total Score at Week 16

The Young Mania Rating Scale (YMRS) is an 11-item scale that assesses manic symptoms based on the patient's perception of his or her condition over the previous 48 hours, as well as the physician's clinical observations during the interview. The 11 items are elevated mood, increased motor activity-energy, sexual interest, sleep, irritability, rate and amount of speech, language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight. The severity of each item is rated on a 5-point (0-4) or a 9-point (0-8) scale. The total score of all 11 items can range from 0 to 60. A higher score indicates worse manic symptoms. A negative change score indicates improvement.

Time frame:
Baseline to Week 16
Reported as:
Mean · Units on a scale
Change From Baseline in the YMRS Total Score at Week 16
Units on a scaleCariprazine 3-12 mg/Day for 16 Weeks
Change From Baseline in the YMRS Total Score at Week 16-15.2 ± 9.2
SecondaryChange From Baseline in the MADRS Total Score at Week 16

The Montgomery-Asberg Depression Rating Scale (MADRS) is a clinician-rated scale that evaluates the patient's depressive symptomatology during the previous week. Patients are rated on 10 items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item is scored on a 7-point (0-6) scale. The total score can range from 0 to 42. A higher score indicates greater depressive symptomatology. A negative change score indicates improvement.

Time frame:
Baseline to Week 16
Reported as:
Mean · Units on a scale
Change From Baseline in the MADRS Total Score at Week 16
Units on a scaleCariprazine 3-12 mg/Day for 16 Weeks
Change From Baseline in the MADRS Total Score at Week 16-1.6 ± 7.5

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cariprazine 3-12 mg/Day for 16 Weeks0/402 (0%)34/402 (8.5%)293/402 (72.9%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventCariprazine 3-12 mg/Day for 16 Weeks
ManiaPsychiatric disorders9/402
DepressionPsychiatric disorders5/402
AkathisiaPsychiatric disorders3/402
Suicidal ideationPsychiatric disorders2/402
Suicide attemptPsychiatric disorders2/402
Angina pectorisCardiac disorders1/402
AnxietyPsychiatric disorders1/402
AsthmaRespiratory, thoracic and mediastinal disorders1/402
Bipolar I disorderPsychiatric disorders1/402
BradycardiaCardiac disorders1/402
Most frequent other events
Showing 10 of 15
Most frequent other events
EventCariprazine 3-12 mg/Day for 16 Weeks
AkathisiaNervous system disorders129/402
HeadacheNervous system disorders69/402
ConstipationGastrointestinal disorders44/402
NauseaGastrointestinal disorders42/402
DyspepsiaGastrointestinal disorders38/402
ToothacheGastrointestinal disorders35/402
Back painMusculoskeletal and connective tissue disorders32/402
TremorNervous system disorders31/402
Extrapyramidal disorderNervous system disorders28/402
InsomniaPsychiatric disorders27/402

Baseline characteristics

Safety population: All enrolled participants who took at least 1 dose of investigational product.

Age, Continuous
Age, Continuous(years)Cariprazine 3-12 mg/Day for 16 Weeks
Mean41.4 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)Cariprazine 3-12 mg/Day for 16 Weeks
Female172
Male230
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cariprazine 3-12 mg/Day for 16 Weeks
Hispanic or Latino32
Not Hispanic or Latino370
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cariprazine 3-12 mg/Day for 16 Weeks
American Indian or Alaska Native6
Asian4
Native Hawaiian or Other Pacific Islander1
Black or African American182
White206
More than one race3
Unknown or Not Reported0
Weight
Weight(kg)Cariprazine 3-12 mg/Day for 16 Weeks
Mean86.52 ± 17.83
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Cariprazine 3-12 mg/Day for 16 Weeks
Mean29.21 ± 5.34
Waist circumference
Waist circumference(cm)Cariprazine 3-12 mg/Day for 16 Weeks
Mean97.86 ± 14.05
08

Study locations

35 sites
  • Forest Investigative Site 015
    Springdale, Arkansas 72764, United States
  • Forest Investigative Site 010
    Carson, California 90746, United States
  • Forest Investigative Site 020
    Cerritos, California 90703, United States
  • Forest Investigative Site 009
    Escondido, California 92025, United States
  • Forest Investigative Site 004
    Garden Grove, California 92845, United States
  • Forest Investigative Site 016
    San Diego, California 92102, United States
  • Forest Investigative Site 007
    Santa Ana, California 92701, United States
  • Forest Investigative Site 023
    Washington, District of Columbia 20016, United States
  • Forest Investigative Site 001
    Bradenton, Florida 34208, United States
  • Forest Investigative Site 006
    Fort Lauderdale, Florida 33308, United States
  • Forest Investigative Site 013
    Kissimmee, Florida 34741, United States
  • Forest Investigative Site 021
    Rockville, Maryland 20850, United States
  • Forest Investigative Site 024
    Flowood, Mississippi 39232, United States
  • Forest Investigative Site 022
    Creve Coeur, Missouri 63141, United States
  • Forest Investigative Site 003
    Saint Charles, Missouri 63301, United States
  • Forest Investigative Site 025
    Saint Louis, Missouri 63118, United States
  • Forest Investigative Site 012
    Las Vegas, Nevada 89102, United States
  • Forest Investigative Site 002
    Willingboro, New Jersey 08046, United States
  • Forest Investigative Site 005
    Cincinnati, Ohio 45219, United States
  • Forest Investigative Site 011
    Oklahoma City, Oklahoma 73112, United States
  • Forest Investigative Site 017
    Austin, Texas 78731, United States
  • Forest Investigative Site 014
    Austin, Texas 78754, United States
  • Forest Investigative Site 018
    DeSoto, Texas 75115, United States
  • Forest Investigative Site 019
    Houston, Texas 77008, United States
  • Forest Investigative Site 309
    Gyula, Bekes 5700, Hungary
  • Forest Investigative Site 301
    Budapest, 1083, Hungary
  • Forest Investigative Site 302
    Budapest, 1135, Hungary
  • Forest Investigative Site 306
    Nyiregyhaza, 4400, Hungary
  • Forest Investigative Site 308
    Szombathely, 9700, Hungary
  • Forest Investigative Site 402
    Tuszyn, Kodz 95-080, Poland
  • Forest Investigative Site 404
    Katowice, Silesian 40-340, Poland
  • Forest Investigative Site 407
    Gdansk, 80-952, Poland
  • Forest Investigative Site 401
    Gorlice, 38-300, Poland
  • Forest Investigative Site 408
    Swiecie, 86-100, Poland
  • Forest Investigative Site 505
    Barcelona, 08036, Spain
09

References and documents

Publications

  • Ketter TA, Sachs GS, Durgam S, Lu K, Starace A, Laszlovszky I, Nemeth G. The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study. J Affect Disord. 2018 Jan 1;225:350-356. doi: 10.1016/j.jad.2017.08.040. Epub 2017 Aug 18. PubMed 28843918 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2010 to primary completion in Feb 2012, 24 months.

Results were first posted in Jun 2019, 7 years 3 months after primary completion. A results delay was requested in Dec 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2010
First posted
Feb 1, 2010
StartActual
Feb 28, 2010
Primary completionActual
Feb 29, 2012
CompletionActual
Feb 29, 2012
Results delay requested
Dec 6, 2012
Results first posted
Jun 13, 2019
Last update
Jun 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01059539
Collaborators
Gedeon Richter Ltd.
Responsible party
Sponsor
First posted
Feb 1, 2010
Start date
Feb 28, 2010
Primary completion
Feb 29, 2012
Completion
Feb 29, 2012
Results posted
Jun 13, 2019
Last update
Jun 13, 2019

Study contacts

Elizabeth Diaz, MD
study director · Forest Laboratories

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion